Key clinical point: An immune-related adverse event (irAE) during initial treatment with an immune checkpoint inhibitor does not necessarily preclude a rechallenge.

Major finding: After a mild or severe irAE, anti–PD-1 or anti–PD-L1 therapy readministration was associated with the occurrence of a second immune-related adverse event in 55% of cases. When a second irAE occurred, it was not more severe than the first.

Study details: The cohort study included 93 consecutive adult patients who were referred over an 18-month period to the ImmunoTOX assessment board at the Gustave Roussy cancer center in Villejuif, France and followed for at least 1 year.

Disclosures: The study was supported by the Gustave Roussy cancer center and Gustave Roussy immunotherapy program. Dr. Simonaggio had no relevant disclosures; several coauthors reported consultancy fees and research support from multiple drug companies.